The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

NCT03152084 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Poor recruitment.

Conditions

Diabetes Mellitus, Type 2
Kidney Function Tests

Interventions

DRUG: Dapagliflozin

Sponsor

AstraZeneca